FGFR2 Gene Activation
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors (NCT04526106) | Elevar Therapeutics | 2020-09-02 |
Track FGFR2 Gene Activation automatically
Every clearance here is in the API, with alerts when new ones post.